Twist Bioscience Corporation (TWST)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Emily Marine Leproust Ph.D.
|
Co-Founder, Board Chair & CEO | 1.78M | -- | 1973 |
|
Dr. Patrick John Finn Ph.D.
|
President & COO | 1.27M | -- | 1972 |
|
Mr. Adam Laponis
|
Chief Financial Officer | 850.69k | -- | 1977 |
|
Mr. Dennis Cho J.D.
|
Chief Legal Officer & Corporate Secretary | 749.01k | -- | 1971 |
|
Ms. Paula Green
|
Senior Vice President of Human Resources | 778.32k | -- | 1968 |
|
Mr. Robert F. Werner
|
VP & Chief Accounting Officer | -- | -- | 1973 |
|
Mr. Siyuan Chen
|
Chief Technology Officer | -- | -- | -- |
|
Dr. Michael Fero Ph.D.
|
Chief Information Officer | -- | -- | -- |
|
Dr. Colby Souders Ph.D.
|
Chief Scientific Officer | -- | -- | -- |
|
Ms. Nicole Moreno
|
Senior Vice President of Sales & Support | -- | -- | -- |
Twist Bioscience Corporation
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 979
Description
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Corporate Governance
Upcoming Events
November 12, 2026 at 12:30 PM UTC
Twist Bioscience Corporation Earnings Date
